awmsg logo



abatacept (Orencia®)


Reference No. 2

Publication date:
27/02/2014


Last review date:
17/02/2017

Appraisal information

abatacept (Orencia®) 250 mg powder for concentrate for solution for infusion


Company: Bristol-Myers Squibb Pharmaceuticals Ltd
BNF category: Musculoskeletal and joint diseases
NMG meeting date: 27/11/2013
AWMSG meeting date: 15/01/2014
   
   
Submission Type: Full Submission
Status: Superseded
Advice No: 0114
Ministerial ratification: 26/02/2014

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA373) NICE GUIDANCE ISSUED DECEMBER 2015 (Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology) Abatacept (Orencia®) is recommended as an option for use within NHS Wales in combination with methotrexate for the treatment of moderate to severe active polyarticular juvenile idiopathic arthritis in paediatric patients 6 years of age and older who have had an insufficient response to other disease-modifying anti-rheumatic drugs including at least one tumour necrosis factor inhibitor. This recommendation applies only in circumstances where the approved Patients Access Scheme is utilised.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download